{"entity":{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","aka":[],"tldr":"Ryan Sullivan is a melanoma trialist and a leading voice on managing immunotherapy side effects.","summary":"Ryan J. Sullivan is Associate Director of the Melanoma Program at Massachusetts General Hospital Cancer Center. He is a melanoma trialist and a leading voice on managing the side effects of immunotherapy, having co-authored society guidelines on immune-related adverse events. His selected paper is the ASCO guideline update on managing immune-related adverse events in patients treated with immune checkpoint inhibitors. He leads melanoma clinical trials at MGH and studies how to sequence targeted and immune therapy, including DREAMseq-style questions.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19412/ryan-sullivan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Melanoma Program","institutionId":"mgh","specialisms":["Melanoma","Immune-related adverse events","Targeted and immune therapy sequencing"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19412/ryan-sullivan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D"}],"papers":[{"title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","journal":"Journal of Clinical Oncology","year":2021},{"title":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet"}]},"route":"/people/ryan-sullivan/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"institution":[{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/"}],"paper":[{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/"}]}}